CN1513519A - Heart quieting and orifice opening capsule and its preparation - Google Patents
Heart quieting and orifice opening capsule and its preparation Download PDFInfo
- Publication number
- CN1513519A CN1513519A CNA031371302A CN03137130A CN1513519A CN 1513519 A CN1513519 A CN 1513519A CN A031371302 A CNA031371302 A CN A031371302A CN 03137130 A CN03137130 A CN 03137130A CN 1513519 A CN1513519 A CN 1513519A
- Authority
- CN
- China
- Prior art keywords
- grams
- gram
- radix
- rhizoma
- resuscitation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims description 6
- 239000003814 drug Substances 0.000 claims abstract description 28
- 241000207929 Scutellaria Species 0.000 claims abstract description 3
- 238000010438 heat treatment Methods 0.000 claims abstract description 3
- 230000001954 sterilising effect Effects 0.000 claims abstract description 3
- 230000001914 calming effect Effects 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000011021 lapis lazuli Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 235000012239 silicon dioxide Nutrition 0.000 claims description 4
- 241000202807 Glycyrrhiza Species 0.000 claims description 2
- 241000208966 Polygala Species 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000004744 fabric Substances 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- 230000005070 ripening Effects 0.000 claims description 2
- 239000007779 soft material Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 239000003643 water by type Substances 0.000 claims description 2
- 239000008361 herbal raw material Substances 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- 241000271309 Aquilaria crassna Species 0.000 abstract 1
- 206010004542 Bezoar Diseases 0.000 abstract 1
- 241000218202 Coptis Species 0.000 abstract 1
- 235000002991 Coptis groenlandica Nutrition 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 12
- 229940079593 drug Drugs 0.000 description 9
- 238000012360 testing method Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000020016 psychiatric disease Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 230000001107 psychogenic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine in the form of capsule for treating schizophrenia is prepared from 14 Chinese-medicinal materials including eagle wood, artificial bezoar, coptis root, scutellaria root, etc through pretreating, proportioning, heating, sterilizing, granulating and loading in capsules. Its advantage is high curative effect.
Description
The present invention relates to schizoid medicine of a kind of treatment and preparation method thereof, is the Chinese patent medicine that raw material is made with the Chinese herbal medicine specifically, the invention still further relates to the manufacture method of this medicine.
The schizophrenia traditional Chinese medical science belongs to demented, is the frequently-occurring disease of serious harm human health, and China's prevalence is at present: the inferior crowd of economic level is 10.16 ‰, and economic level is first-class to be 4.75 ‰.Account for China psychosis inpatients people's about 50%, account for chronic mental illness people's about 60%, the primary disease frequently-occurring disease also is the common psychosis the closest with criminal behavior in person between twenty and fifty.
The general unconscious and disturbance of intelligence of schizophrenia, normal performance have the inharmonious of the obstacle of aspects such as special thinking, consciousness, emotion and behavior and ergasia and environment.The cause of disease of primary disease and pathogeny, treatment and prevention are the central topics of psychiatry research tackling key problem always.Just, run into the problem of the following aspects both at home and abroad to schizoid Drug therapy:
1, based on the Western medicine chlorpromazine be the medicine of representative, be 8～10 weeks the general course of treatment, though respond well, more obvious to cardiovascular and liver function influence, dosage is also bigger.
2, folklore the schizoid folk prescription of many treatments, generally all is the alkaloids Chinese medicine of the inhibition nervus centralis of single or two to three flavors, and bone marrow is had excitation more.
Though 3 also have some to treat schizoid Chinese patent medicine, because Time of Administration is longer, effect is not fairly obvious, injures taste, and the patient still depends on some Western medicine.
The object of the present invention is to provide a kind of effect of eliminating the phlegm by flat contrary, the suppressing the hyperactive liver to relieve the wind syndrome of drink, sending down the abnormal ascending QI, clearing away heat-fire, tranquillizing and allaying excitement that has, it is less to take the back side effect, and effect is sure, the treatment of schizophrenia medicament for the treatment of both the principal and secondary aspects of a disease.
Another object of the present invention provides a kind of preparation method for the treatment of schizophrenia drug.
Solution of the present invention is based on Chinese medicine and pharmacy to schizoid etiology and pathology understanding and Therapeutic Principle, with reference to the modern scientific research achievement, from Chinese herbal medicine, filter out and having the natural Chinese medicine that eliminates the phlegm by flat contrary, the suppressing the hyperactive liver to relieve the wind syndrome of drink, sending down the abnormal ascending QI, clearing away heat-fire, tranquillizing and allaying excitement, according to theory of Chinese medical science, determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs, make it bring into play the collaborative opsonic action of all medicines, prevent and treat schizoid the development.
A kind of schizophrenia drug for the treatment of of the present invention is made by following prescription and weight:
Lapis Micae Aureus 300 gram Lignum Aquilariae Resinatum 100 gram Rhizoma Coptidis 200 gram Radix Scutellariaes 200 gram artificial Calculus Boviss 50 grams
Fructus Gardeniae 300 gram Radix Et Rhizoma Rhei 200 gram Radix Polygalaes 300 gram Radix Glycyrrhizaes 50 cron Radix Gentianae 200 grams
Radix Curcumae 200 gram Cornu Saigae Tataricae 150 gram Rhizoma Acori Graminei 300 gram Concretio silicea Bambusae seu schizostachyi 200 grams
The method that above-mentioned each proportioning Chinese herbal medicine is made medicine of the present invention is: after earlier Lapis Micae Aureus 300 grams, artificial Calculus Bovis's 50 grams, Cornu Saigae Tataricae 150 grams, Concretio silicea Bambusae seu schizostachyi 200 grams being cleaned, it is standby to be crushed to 300 mesh sieve impalpable powders; Lignum Aquilariae Resinatum 100 grams, Rhizoma Coptidis 200 grams, Radix Scutellariae 200 grams, Radix Polygalae 300 grams, Radix Glycyrrhizae 50 grams, Radix Gentianae 200 grams, Radix Curcumae 200 grams, Rhizoma Acori Graminei 300 grams, Fructus Gardeniae 300 grams, Radix Et Rhizoma Rhei 200 gram waters are decocted three times, 2 hours for the first time, second and third time each 1 hour, three filtrates are mixed, heating is condensed into thick paste and above-mentioned standby fine powder mixing, detect, ripening under 100～110 ℃ of temperature, sterilization 20～40 minutes, spray is made soft material with 45% ethanol, be pressed through screen cloth No. 1, the Capsules shell of packing into after the drying is made capsule.
Characteristics of the present invention are that medicament is easy to use, have no side effect, and can see positive effect in a short time.The animal acute toxicity test of medicine of the present invention is as follows:
Test unit: institute for drug control, Zhengzhou City pharmacological room
Date of test: on June 23,16 days to 1998 June in 1998
Result of the test: a kind of treatment schizophrenia drug and preparation method thereof (calming heart for resuscitation capsule) mice once-a-day, the maximum tolerated dose of gastric infusion is 1333.3g (crude drug)/kg, is equivalent to 400.4 times with dosage of clinical plan.Animal activity, outward appearance sign after the administration, cut open inspection and there is no unusually, feces is black, and normal, body weight gain is normal, no dead animal.The body weight determination of mice mtd test the results are shown in Table 1.
The body weight determination of table 1 calming heart for resuscitation capsule mice mtd test
Date of observation
0 1 3 5 7
20.10 21.65 21.90 22.88 22.15
±1.19 ±2.17 ±2.20 ±2.56 ±2.82
Annotate: X ± SD n=20
Medicine of the present invention carries out the observation treatment of overall process to 108 routine inpatients, wherein male 62 examples, and women 46 examples, the oldest person 60 years old, reckling 16 years old is cured 92 people that leave hospital, produce effects 16 people, total effective rate reaches 100%.Therapeutic outcome sees Table 2
Table 2 calming heart for resuscitation capsule for treating 108 routine patient's observation of curative effect
Total sick produce effects of curing is invalid
Type
The example numerical example is counted % example number % example number %
Schizophrenia 50 46 92.0 4 8.0 00
Schizophreniform psychosis 18 16 88.9 2 11.1 00
Acute psychogenic mental disorder 15 14 93.4 1 6.6 00
Mania 15 13 86.7 2 13.3 00
Epilepsy associated mental disorder 10 8 82.0 2 20.0 00
Test statistics shows: medicine of the present invention is to schizophrenia and acute psychogenic mental disorder best results.
Medicine of the present invention is by clinical application practice, and is useful to patients such as schizophrenia, removed human spirit's obstacle, demonstrates wide practical prospect and potentiality to be exploited.
Claims (3)
1, the capsular medicine of a kind of calming heart for resuscitation is characterized in that it is the medicament of being made by following herbal raw material proportioning:
Lapis Micae Aureus 300 gram Lignum Aquilariae Resinatum 100 gram Rhizoma Coptidis 200 gram Radix Scutellariaes 200 gram artificial Calculus Boviss 50 grams
Fructus Gardeniae 300 gram Radix Et Rhizoma Rhei 200 gram Radix Polygalaes 300 gram Radix Glycyrrhizaes 50 cron Radix Gentianae 200 grams
Radix Curcumae 200 gram Cornu Saigae Tataricae 150 gram Rhizoma Acori Graminei 300 gram Concretio silicea Bambusae seu schizostachyi 200 grams
2, a kind of calming heart for resuscitation pharmaceutical capsules according to claim 1 is characterized in that said medicament is a capsule.
3, a kind of preparation aforesaid right requires described a kind of calming heart for resuscitation pharmaceutical capsules method, and after it is characterized in that earlier Lapis Micae Aureus 300 grams, artificial Calculus Bovis's 50 grams, Cornu Saigae Tataricae 150 grams, Concretio silicea Bambusae seu schizostachyi 200 grams being cleaned, it is standby to be crushed to 300 mesh sieve impalpable powders; Lignum Aquilariae Resinatum 100 grams, Rhizoma Coptidis 200 grams, Radix Scutellariae 200 grams, Radix Polygalae 300 grams, Radix Glycyrrhizae 50 grams, Radix Gentianae 200 grams, Radix Curcumae 200 grams, Rhizoma Acori Graminei 300 grams, Radix Et Rhizoma Rhei 200 grams, Fructus Gardeniae 300 gram waters are decocted three times, 2 hours for the first time, second and third time each 1 hour, three filtrates are mixed, heating is condensed into thick paste and above-mentioned standby fine powder mixing, detect, ripening under 100～110 ℃ of temperature, sterilization 20～40 minutes, spray is made soft material with 45% ethanol, be pressed through screen cloth No. 1, the Capsules shell of packing into after the drying is made capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031371302A CN100408080C (en) | 2003-06-04 | 2003-06-04 | Heart quieting and orifice opening capsule and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031371302A CN100408080C (en) | 2003-06-04 | 2003-06-04 | Heart quieting and orifice opening capsule and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1513519A true CN1513519A (en) | 2004-07-21 |
| CN100408080C CN100408080C (en) | 2008-08-06 |
Family
ID=34240105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031371302A Expired - Fee Related CN100408080C (en) | 2003-06-04 | 2003-06-04 | Heart quieting and orifice opening capsule and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100408080C (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101579511B (en) * | 2009-07-02 | 2011-08-31 | 陈雪梅 | Drug combination used for treating schizophrenia |
| CN102302734A (en) * | 2011-08-30 | 2012-01-04 | 高新华 | Agent for treating insomnia |
| CN102526381A (en) * | 2010-12-27 | 2012-07-04 | 黑龙江康元神经专科医院有限责任公司 | Traditional Chinese medicine preparation for treating schizophrenia |
| CN102657786A (en) * | 2012-03-22 | 2012-09-12 | 翟爱玲 | Drinking potion for treating mania |
| CN103272190A (en) * | 2013-06-24 | 2013-09-04 | 陈焕微 | Chinese herbal compound for curing invasion of pericardium by evil, sleep talking and delirious speech |
| CN103285266A (en) * | 2013-07-02 | 2013-09-11 | 李伟丽 | Chinese medicine composition for treating schizophrenia |
| CN106620544A (en) * | 2017-03-07 | 2017-05-10 | 李子义 | Medicine for treating schizophrenia and preparation method of medicine |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1382473A (en) * | 2002-05-21 | 2002-12-04 | 崔行善 | Medicine for treating psychic diseases |
-
2003
- 2003-06-04 CN CNB031371302A patent/CN100408080C/en not_active Expired - Fee Related
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101579511B (en) * | 2009-07-02 | 2011-08-31 | 陈雪梅 | Drug combination used for treating schizophrenia |
| CN102526381A (en) * | 2010-12-27 | 2012-07-04 | 黑龙江康元神经专科医院有限责任公司 | Traditional Chinese medicine preparation for treating schizophrenia |
| CN102302734A (en) * | 2011-08-30 | 2012-01-04 | 高新华 | Agent for treating insomnia |
| CN102302734B (en) * | 2011-08-30 | 2013-01-16 | 高新华 | Agent for treating insomnia |
| CN102657786A (en) * | 2012-03-22 | 2012-09-12 | 翟爱玲 | Drinking potion for treating mania |
| CN103272190A (en) * | 2013-06-24 | 2013-09-04 | 陈焕微 | Chinese herbal compound for curing invasion of pericardium by evil, sleep talking and delirious speech |
| CN103285266A (en) * | 2013-07-02 | 2013-09-11 | 李伟丽 | Chinese medicine composition for treating schizophrenia |
| CN106620544A (en) * | 2017-03-07 | 2017-05-10 | 李子义 | Medicine for treating schizophrenia and preparation method of medicine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100408080C (en) | 2008-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101028507A (en) | Chinese-medicinal composition for treating asthma | |
| CN104338062A (en) | Chinese medicinal preparation for treating stomachache and diarrhea | |
| CN1513519A (en) | Heart quieting and orifice opening capsule and its preparation | |
| CN1048636C (en) | Special Chinese-medicinal preparation for radically dropping drug | |
| CN100411666C (en) | Broad-specturm medicine for treating snake venom poisoning | |
| CN100528214C (en) | Capsule for treating epilepsia and its preparing method | |
| CN104758761A (en) | Traditional Chinese medicine composition for treating bronchial asthma | |
| CN1117865A (en) | "Dianjiankang" - a Chinese proprietary medicine for treatment of epilepsy | |
| CN102861289B (en) | Chinese medicinal drug addiction stopping and three-hyper lowering capsule | |
| CN1081464C (en) | Chinese medicine for acute and chronic diarrhea, dysentery with purulent and bloody stools, as well as acute and chronic colitis | |
| CN1131051C (en) | medicine for treating cervical spondylosis and preparation method thereof | |
| CN101601840B (en) | Medicine for treating hepatolenticular degeneration | |
| CN105879000A (en) | Pharmaceutic preparation for treating tonsillitis and application thereof | |
| CN112220846A (en) | Traditional Chinese medicine composition for treating children's chronic cough and application thereof | |
| CN1164291C (en) | Chinese proprietary for treating protrusion of lumber interverterbral disc and its prepn. | |
| CN1255160C (en) | Health food for preventing and treating influenza | |
| CN105770701B (en) | A traditional Chinese medicine sachet for preventing influenza in children | |
| CN106581468A (en) | Preparation method of traditional Chinese medicine capable of treating gastric ulcer | |
| CN1218737C (en) | Prepared Chinese internal medicine for treating prolapse of intervertebral disc | |
| CN103191338B (en) | Pharmaceutical composition for treating pediatric esophageal achalasia | |
| CN104524266A (en) | Preparation method of ion introduction agent for treating children hyperthyroidism | |
| CN103191335B (en) | Pharmaceutical composition for treating esophageal achalasia | |
| CN103340987B (en) | Pharmaceutical composition for abatement of fever | |
| CN119386132A (en) | A Chinese medicine composition, ointment and application thereof | |
| CN1616042A (en) | Chinese medicine composition for treating chronic bronchitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080806 |